Top

Orphanet Journal of Rare Diseases

Published in:

Open Access 01-12-2015 | Research

Pressure for drug development in lysosomal storage disorders – a quantitative analysis thirty years beyond the US orphan drug act

Authors: Konstantin Mechler, William K Mountford, Georg F Hoffmann, Markus Ries

Published in: Orphanet Journal of Rare Diseases | Issue 1/2015

Abstract

Background

Lysosomal storage disorders are a heterogeneous group of approximately 50 monogenically inherited orphan conditions. A defect leads to the storage of complex molecules in the lysosome, and patients develop a complex multisystemic phenotype of high morbidity often associated with premature death. More than 30 years ago the Orphan Drug Act of 1983 passed the United States legislation intended to facilitate the development of drugs for rare disorders.

We directed our efforts in assessing which lysosomal diseases had drug development pressure and what distinguished those with successful development and approvals from diseases not treated or without orphan drug designation.

Methods

Analysis of the FDA database for orphan drug designations through descriptive and comparative statistics.

Results

Between 1983 and 2013, fourteen drugs for seven conditions received FDA approval. Overall, orphan drug status was designated 70 times for 20 conditions. Approved therapies were enzyme replacement therapies (N = 10), substrate reduction therapies (N = 1), small molecules facilitating lysosomal substrate transportation (N = 3). FDA approval was significantly associated with a disease prevalence higher than 0.5/100,000 (p = 0.00742) and clinical development programs that did not require a primary neurological endpoint (p = 0.00059). Orphan drug status was designated for enzymes, modified enzymes, fusion proteins, chemical chaperones, small molecules leading to substrate reduction, or facilitating subcellular substrate transport, stem cells as well as gene therapies.

Conclusions

Drug development focused on more common diseases. Primarily neurological diseases were neglected. Small clinical trials with either somatic or biomarker endpoints were successful. Enzyme replacement therapy was the most successful technology. Four factors played a key role in successful orphan drug development or orphan drug designations: 1) prevalence of disease 2) endpoints 3) regulatory precedent, and 4) technology platform. Successful development seeded further innovation.

Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281(3):249–54.CrossRefPubMed

Poorthuis BJ, Wevers RA, Kleijer WJ, Groener JE, de Jong JG, van Weely S, et al. The frequency of lysosomal storage diseases in The Netherlands. Hum Genet. 1999;105(1–2):151–6.CrossRefPubMed

Applegarth DA, Toone JR, Lowry RB. Incidence of inborn errors of metabolism in British Columbia, 1969–1996. Pediatrics. 2000;105(1), e10.CrossRefPubMed

Pinto R, Caseiro C, Lemos M, Lopes L, Fontes A, Ribeiro H, et al. Prevalence of lysosomal storage diseases in Portugal. Eur J Hum Genet. 2004;12(2):87–92. doi:10.1038/sj.ejhg.5201044.CrossRefPubMed

Platt F, Walkley S. Lysosomal Disorders of the Brain: Recent Advances in Molecular and Cellular Pathogenesis and Treatment. Oxford: Oxford University Press; 2004.

Haffner ME, Torrent-Farnell J, Maher PD. Does orphan drug legislation really answer the needs of patients? Lancet. 2008;371(9629):2041–4. doi:10.1016/S0140-6736(08)60873-9.

FDA. Search Orphan Drug Designations and Approvals http://www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfm. Accessed 20 Dec 2013.

Orphanet Report Series, Rare Diseases collection, Prevalence of rare diseases: Bibliographic data, November 2013, Number 1: Listed in alphabetical order of disease or group of diseases, http://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_diseases_by_alphabetical_list.pdf Accessed 20 Dec 2013.

Schiffmann R, Fitzgibbon EJ, Harris C, DeVile C, Davies EH, Abel L, et al. Randomized, controlled trial of miglustat in Gaucher's disease type 3. Ann Neurol. 2008;64(5):514–22. doi:10.1002/ana.21491.CrossRefPubMedCentralPubMed

10.

Goker-Alpan O, Wiggs EA, Eblan MJ, Benko W, Ziegler SG, Sidransky E, et al. Cognitive outcome in treated patients with chronic neuronopathic Gaucher disease. J Pediatr. 2008;153(1):89–94. doi:10.1016/j.jpeds.2007.12.023.CrossRefPubMed

11.

Muenzer J, Gucsavas-Calikoglu M, McCandless SE, Schuetz TJ, Kimura A. A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome). Mol Genet Metabol. 2007;90(3):329–37. doi:10.1016/j.ymgme.2006.09.001.CrossRef

12.

Wraith JE, Clarke LA, Beck M, Kolodny EH, Pastores GM, Muenzer J, et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr. 2004;144(5):581–8. doi:10.1016/j.jpeds.2004.01.046.CrossRefPubMed

13.

Harmatz P, Whitley CB, Waber L, Pais R, Steiner R, Plecko B, et al. Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr. 2004;144(5):574–80. doi:10.1016/j.jpeds.2004.03.018.CrossRefPubMed

14.

Altarescu G, Hill S, Wiggs E, Jeffries N, Kreps C, Parker CC, et al. The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher's disease. J Pediatr. 2001;138(4):539–47.CrossRefPubMed

15.

Ries M, Gupta S, Moore DF, Sachdev V, Quirk JM, Murray GJ, et al. Pediatric Fabry disease. Pediatrics. 2005;115(3):e344–55. doi:10.1542/peds.2004-1678.CrossRefPubMed

16.

Ohashi T. Enzyme replacement therapy for lysosomal storage diseases. Pediatr Endocrinol Rev. 2012;10 Suppl 1:26–34.PubMed

17.

Strothotte S, Strigl-Pill N, Grunert B, Kornblum C, Eger K, Wessig C, et al. Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial. J Neurol. 2010;257(1):91–7. doi:10.1007/s00415-009-5275-3.CrossRefPubMed

18.

Schiffmann R, Askari H, Timmons M, Robinson C, Benko W, Brady RO, et al. Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing. J Am Soc Nephrol. 2007;18(5):1576–83. doi:10.1681/ASN.2006111263.CrossRefPubMedCentralPubMed

19.

Levin SW, Baker EH, Zein WM, Zhang Z, Quezado ZM, Miao N et al. Oral cysteamine bitartrate and N-acetylcysteine for patients with infantile neuronal ceroid lipofuscinosis: a pilot study. Lancet Neurol. 2014;13(8):777–87. doi:10.1016/S1474-4422(14)70142-5.

20.

Patterson MC, Vecchio D, Prady H, Abel L, Wraith JE. Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Lancet Neurol. 2007;6(9):765–72. doi:10.1016/S1474-4422(07)70194-1.

21.

Clinicaltrials.gov. search terms: lysosomal | Open Studies | Interventional Studies https://clinicaltrials.gov/ct2/results?term=lysosomal&recr=Open&type=Intr&pg=4. Accessed 20 Feb 2015.

22.

Gershon RC, Cella D, Fox NA, Havlik RJ, Hendrie HC, Wagster MV. Assessment of neurological and behavioural function: the NIH Toolbox. Lancet Neurol. 2010;9(2):138–9. doi:10.1016/S1474-4422(09)70335-7.

23.

Bradbury AM, Gray-Edwards HL, Shirley JL, McCurdy VJ, Colaco AN, Randle AN, et al. Biomarkers for disease progression and AAV therapeutic efficacy in feline Sandhoff disease. Exp Neurol. 2015;263:102–12. doi:10.1016/j.expneurol.2014.09.020.CrossRefPubMed

24.

FDA. Laronidase Product Approval Information - Licensing Action http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080438.htm. Accessed 20 Dec 2013.

25.

FDA. Drug Approval Package: Elaprase (Idursulfase) NDA # 125151 http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/125151s0000_ElapraseTOC.cfm. Accessed 20 Dec 2013.

26.

FDA. Drug Approval Package: Naglazyme (Galsulfase) NDA #125117 http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/125117s000_NaglazyneTOC.cfm. Accessed 20 Dec 2013.

27.

FDA. CEREDASE, NDA no. 020057, label http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/020057s034lbl.pdf. Accessed 20 Dec 2013.

28.

FDA. CEREZYME, NDA no. 020367, label http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/20367s066lbl.pdf. Accessed 20 Dec 2013.

29.

FDA. Drug Approval Package Elelyso (Taliglucerase alfa) http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022458Orig1s000TOC.cfm. 20 Dec 2013.

30.

FDA. Drug Approval Package Vpriv (Velaglucerase alfa) http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022575s000TOC.cfm] Accessed 20 Dec 2013.

31.

FDA. Drug Approval Package Zavesca (Miglustat) http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-348_Zavesca.cfm. Accessed 20 Dec 2013.

32.

FDA. Agalsidase beta Product Approval Information - Licensing Action 4/24/03 http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080585.htm. Accessed 20 Dec 2013.

33.

FDA. Drug Approval Package: Myozyme (Alglucosidase Alfa) NDA #125141 http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/125141s000_MyozymeTOC.cfm]. Accessed 20 Dec 2013.

34.

FDA. Drug Approval Package Lumizyme (alglucosidase alfa) http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/125291s000TOC.cfm.

35.

FDA. CYSTAGON, NDA no. 020392, label http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/020392s010lbl.pdf. Accessed 20 Dec 2013.

36.

FDA. Drug Approval Package Cystaran (cysteamine ophthalmic solution) 0.44%, NDA # 200740 http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/200740_cystaran_toc.cfm. Accessed 20 Dec 2013.

37.

FDA. PROCYSBI, NDA no. 203389, label http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203389s000lbl.pdf. Accessed 20 Dec 2013.

Title: Pressure for drug development in lysosomal storage disorders – a quantitative analysis thirty years beyond the US orphan drug act
Authors: Konstantin Mechler
William K Mountford
Georg F Hoffmann
Markus Ries
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: Orphanet Journal of Rare Diseases / Issue 1/2015
Electronic ISSN: 1750-1172
DOI: https://doi.org/10.1186/s13023-015-0262-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Pressure for drug development in lysosomal storage disorders – a quantitative analysis thirty years beyond the US orphan drug act

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2015

A nationwide survey of hereditary angioedema due to C1 inhibitor deficiency in Italy

Assessment of the impact of phenylketonuria and its treatment on quality of life of patients and parents from seven European countries

A cross-sectional controlled developmental study of neuropsychological functions in patients with glutaric aciduria type I

Idiopathic (primary) achalasia: a review

Genotype and phenotype analysis of Taiwanese patients with osteogenesis imperfecta

Rare genetic disease in China: a call to improve clinical services